论文部分内容阅读
普遍认为大多数宫颈浸润癌及高级别癌前病变与高危型人类乳头状病毒(HPV)有关。一种新型HPV检测法即PCR扩增酶联免疫吸附法(PCRELISA)可在阴道镜取得的大多数宫颈癌及高级别宫颈病变标本中检出HPV。 PCR-ELISA选E_6开读框架区为扩增区。由于E_6基因产物与HPV致癌过程有关,所以这个癌基因应在与HPV有关的宫颈癌及高级别癌前病变中表达。不同的HPV类型中编码E_6的DNA序例不同,故能够确定特异识别高危型HPV序列的引物及探针。所选择的引物及探针与HPV-16、18、31、33、35、39、45、56、58、65型同源,或仅为一个核苷酸序列不同,而HPV-6、11、30、32、34、42、51、52、53型有多个核苷酸序列不同,然后从HPV-6、11、16、18、31、33、
It is generally accepted that most cervical invasive carcinomas and high-grade precancerous lesions are associated with high-risk human papillomavirus (HPV). A new HPV test, PCR amplification enzyme-linked immunosorbent assay (PCRELISA), detects HPV in most cervical cancers and high-grade cervical lesions obtained with colposcopy. PCR-ELISA selected E_6 open reading frame area for amplification. Since the E_6 gene product is involved in the oncogenic process of HPV, this oncogene should be expressed in HPV-related cervical cancers and in high-grade precancerous lesions. Different DNA types encode different sequences of E_6 DNA, making it possible to identify primers and probes that specifically recognize high-risk HPV sequences. The selected primers and probes are homologous to HPV-16, 18, 31, 33, 35, 39, 45, 56, 58, 65, or differ only in one nucleotide sequence, 30, 32, 34, 42, 51, 52, and 53 differ in their nucleotide sequences and then selected from HPV-6, 11, 16, 18, 31, 33,